Decheng Capital’s Terns Pharmaceuticals TERN Stock Holding History

Decheng Capital’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-714,285	Closed	-$4.64M	–	29
2023 Q4	$4.64M	Buy	+714,285	New	+$3.78M	1.3%	15

Other funds holding TERN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Decheng Capital's TERN Position: Q1 2024 in Review

Decheng Capital sold out of Terns Pharmaceuticals (TERN) in Q1 2024, closing a stake of 714,285 shares — an estimated $4.64M sold.

Decheng Capital first reported a position in TERN in Q4 2023 and held it in 1 quarter. The position peaked at $4.64M in Q4 2023. 112 funds tracked by Wall St. Rank hold TERN as of Q1 2024.

Decheng Capital reported no remaining Terns Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Decheng Capital sold 714,285 Terns Pharmaceuticals shares in Q1 2024, an estimated $4.64M.
Decheng Capital first reported a position in Terns Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Decheng Capital's Terns Pharmaceuticals position peaked at $4.64M in Q4 2023.
112 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2024.

Based on Decheng Capital's 13F filing for Q1 2024, filed 14 May 2024.